Investigational Drug Information for Taselisib
✉ Email this page to a colleague
What is the drug development status for Taselisib?
Taselisib is an investigational drug.
There have been 10 clinical trials for Taselisib.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 9th 2015.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Genentech, Inc., and Southwest Oncology Group.
There are one hundred and eighteen US patents protecting this investigational drug and zero international patents.
Summary for Taselisib
| US Patents | 118 |
| International Patents | 1,651 |
| US Patent Applications | 526 |
| WIPO Patent Applications | 435 |
| Japanese Patent Applications | 86 |
| Clinical Trial Progress | Phase 3 (2015-04-09) |
| Vendors | 57 |
Recent Clinical Trials for Taselisib
| Title | Sponsor | Phase |
|---|---|---|
| Trial of Taselisib in Overgrowth | Centre Hospitalier Universitaire Dijon | Phase 1/Phase 2 |
| Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) | National Cancer Institute (NCI) | Phase 2 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Taselisib
Top disease conditions for Taselisib
Top clinical trial sponsors for Taselisib
US Patents for Taselisib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Taselisib | ⤷ Sign Up | Substituted thiohydantoin derivatives as androgen receptor antagonists | Janssen Pharmaceutica NV (Beerse, BE) | ⤷ Sign Up |
| Taselisib | ⤷ Sign Up | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Sign Up |
| Taselisib | ⤷ Sign Up | Heterocyclic estrogen receptor modulators and uses thereof | Genentech, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| Taselisib | ⤷ Sign Up | Compounds and combinations for the treatment of HIV | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Taselisib | ⤷ Sign Up | Tricyclic PI3K inhibitor compounds and methods of use | Genentech, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| Taselisib | ⤷ Sign Up | Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13A- octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Taselisib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Taselisib | Argentina | AR107432 | 2036-01-11 | ⤷ Sign Up |
| Taselisib | Australia | AU2017207268 | 2036-01-11 | ⤷ Sign Up |
| Taselisib | Australia | AU2019203280 | 2036-01-11 | ⤷ Sign Up |
| Taselisib | Australia | AU2021201018 | 2036-01-11 | ⤷ Sign Up |
| Taselisib | Brazil | BR112018014015 | 2036-01-11 | ⤷ Sign Up |
| Taselisib | Canada | CA3010509 | 2036-01-11 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
